Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 2/20 | 0.76 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.76 |
| ▸ | CDK1 | P06493 | 1/20 | 0.76 |
| ▸ | CDK2 | P24941 | 1/20 | 0.76 |
| ▸ | GSK3B | P49841 | 1/20 | 0.76 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.76 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.76 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.76 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.76 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.76 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.76 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.76 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 0.76 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.76 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.76 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.76 |
| ▸ | DRD2 | P14416 | 11/20 | 0.38 |
| ▸ | DRD3 | P35462 | 11/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd-1080 SCHEMBL30298327 | 0.87 | CDK7 (1.00) | CDK7DYRK3CDK1CDK2GSK3B | |
| Azd-1080 SCHEMBL29374248 | 0.87 | CDK7 (1.00) | CDK7DYRK3CDK1CDK2GSK3B | |
| Azd-1080 SCHEMBL394519 | 0.87 | CDK7 (1.00) | CDK7DYRK3CDK1CDK2GSK3B | |
| Azd-1080 SCHEMBL29361806 | 0.87 | CDK7 (1.00) | CDK7DYRK3CDK1CDK2GSK3B | |
| Azd-1080 SCHEMBL3701569 | 0.87 | CDK7 (1.00) | CDK7DYRK3CDK1CDK2GSK3B | |
| Azd-1080 SCHEMBL395245 | 0.86 | CDK7 (0.98) | CDK7DYRK3CDK1CDK2GSK3B | |
| SCHEMBL7865827 | 0.85 | CDK5 (0.55) | CDK7DYRK3CDK1CDK2GSK3B | |
| SCHEMBL4016405 | 0.85 | CDK7 (0.83) | CDK7DYRK3CDK1CDK2GSK3B | |
| SCHEMBL4062352 | 0.85 | CDK7 (0.83) | CDK7DYRK3CDK1CDK2GSK3B | |
| SCHEMBL4019774 | 0.84 | CDK7 (0.82) | CDK7DYRK3CDK1CDK2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318793-B2 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | ABBOTT GMBH & CO. KG (DE) | 2012-11-27 | — | — | US | claimed |
| EP-2411379-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBVIE DEUTSCHLAND (DE) | 2014-12-17 | — | — | EP | disclosed |
| EP-2411379-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBVIE DEUTSCHLAND (DE) | 2014-12-17 | — | — | EP | disclosed |
| US-8318793-B2 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | ABBOTT GMBH & CO. KG (DE) | 2012-11-27 | — | — | US | disclosed |
| US-8318793-B2 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | ABBOTT GMBH & CO. KG (DE) | 2012-11-27 | — | — | US | disclosed |
| US-8318793-B2 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | ABBOTT GMBH & CO. KG (DE) | 2012-11-27 | — | — | US | disclosed |
| EP-2411379-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | Abbott GmbH & Co. KG (DE) | 2012-02-01 | — | — | EP | disclosed |
| US-20110003810-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2011-01-06 | — | — | US | disclosed |
| US-20110003810-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2011-01-06 | — | — | US | disclosed |
| US-20110003810-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2011-01-06 | — | — | US | disclosed |
| WO-2010109005-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | ABBOTT GMBH & CO. KG (DE) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003810-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 INHIBITORS | GSK3B, GSK3A, GYS2 | CDK7 127/4885DYRK3 538/4885CDK1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.